Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 11, 2004, Pages 1219-1227

  Abergel, Armand ^a   Darcha, Claude ^a   Chevallier, Michèle ^b   Ughetto, Sylvie ^a   Henquell, Cécile ^c   Pol, Stanislas ^d   De Ledinghen, Victor ^e   Canva, Valérie ^f   Bronowicki, Jean Pierre ^g   Tran, Albert ^h   Martineau, Nathalie ^a   Lafeuille, Hélène ^c   Dechelotte, Pierre ^a   Bommelaer, Gilles ^a   Bonny, Corinne ^a  

^a HÔTEL DIEU   (France)

^b Institut Merieux   (France)

^c ONERA   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e HAUT LÉVÊQUE HOSPITAL   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

^h CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Fibrosis; Hepatitis C; Interferon; Ribavirin

Indexed keywords

ALPHA2B INTERFERON; INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; INTERFERONS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 8444245571     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200411000-00022     Document Type: Article

References (28)

1. Camma C, Giunta M, Linea C, Pagliaro L. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. J Hepatol 1997; 26:1187-1199.
2. McHutchinson J, Gordon S, Schiff E, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirine as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-1492.
3. Mallat A, Preaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 1995; 21:1003-1010.
4. Manabe N, Chevallier M, Chossegros P, Causse X, Guerret S, Trepo C, Grimaud JA. Interferon alpha-2b therapy reduces liver fibrosis in chronic non-A non-B hepatitis: a quantitative histological evaluation. Hepatology 1993; 18:1344-1349.
5. Sobesky R, Mathurin P, Charlotte F, Moussali J, Olivi M, Vidaud M, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 1999; 116:378-386.
6. Shiffman M, Hofmann C, Contos M, Luketic V, Sanyal A, Sterling R, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 117:1164-1172.
7. Leroy V, De Traversay C, Barnoud R, Hartman JD, Baud M, Ouzan D, Zarski JP. Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non responders to interferon alfa. J Hepatol 2001; 35:120-126.
8. Poynard T, McHutchinson J, Davis G, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J, for the fibrovirc project group. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32:1131-1137.
9. Poynard T, McHutchinson J, Manns M, Trepo C, Lindsay C, Goodman Z, et al. For the PEG-Fibrosis Group. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122:1303-1313.
10. Knodell R, Ishak K, Black W, Chen T, Craig R, Kaplowitch N, et al. Formulation and application of numerical scoring systems for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 5:431-435.
11. Bedossa P, Poynard T, for the French METAVIR group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24:289-293.
12. Chevallier M, Guerret S, Chossegros P, Gerard F, Grimaud JA. A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies. Hepatology 1994; 20:349-355.
13. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349:825-832.
14. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132:517-524.
15. Fanning L, Loane J, Kenny-Walsh E, Sheehan M, Whelton M, Kirwan W, et al. Tissue viral load variability in chronic hepatitis C. Am J Gastroenterol 2001; 96:3384-3389.
16. The French Metavir Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy in patients with chronic hepatitis C. Hepatology 1994; 20:15-20.
17. Grenard P, Bresson-Hadni S, El Alaoui S, Chevallier M, Vuitton D, Ricard-Blum S. Transglutaminase-mediated cross-linking is involved in the stabilization of extracellular matrix in human liver fibrosis. J Hepatol 2001; 35:367-375.
18. Maharaj B, Maharaj BJ, Leary WP, Coopan RM, Naran AD, Pirie D, Pudifin DJ. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; i:523-525.
19. Vallet-Pichard A, Nalpas B, Fontaine H, Chaix ML, Carnot F, Brechot C, Pol S. Virological and histopathological efficacy of anti-viral therapy in HCV-related cirrhosis. Biennial Meeting of the IASL. April 15-16 2002. J Hepatol 2002; 36 (suppl 1):243.
20. Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aube C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997; 113:1609-1616.
21. Serejo F, Costa A, Oliveira AG, Ramalho F, Batista A, De Moura MC. Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III. Dig Dis Sci 2001; 46:1684-1689.
22. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T, for the MULTIVIRC group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-1075.
23. Rosenberg W. Rating fibrosis progression in chronic liver diseases. J Hepatol 2003; 38:357-360.
24. Ishak K, Baptista A, Bianchi L, Callea F, DeGroote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.
25. Pilette C, Rousselet MC, Bedossa P, Chappard D, Oberti F, Rifflet H, et al. Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol 1998; 28:439-446.
26. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38:1449-1457.
27. Scheuer P. Liver biopsy size matters in chronic hepatitis C: bigger is better. Hepatology 2003; 38:1356-1358.
28. Shiffman ML, Di Bisceglie A, Lindsay K, Morishima S, Wright E, Everson G, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126:1015-1023.